专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021260210A2 ANTI CCR8 ANTIBODY THERAPY: BIOMARKERS & COMBINATION THERAPIES 审中-公开
公开(公告)号：WO2021260210A2
公开(公告)日：2021-12-30
申请号：PCT/EP2021/067580
申请日：2021-06-25
申请人： BAYER AKTIENGESELLSCHAFT , BAYER HEALTHCARE LLC , BAYER INTELLECTUAL PROPERTY GMBH
发明人： BERNDT, Sandra , FILARSKY, Katharina , ELLINGER, Philipp , STELTE-LUDWIG, Beatrix , HOFF, Sabine , ROIDER, Helge , WEBER, Ernst , TRAUTWEIN, Mark , VOTSMEIER, Christian , PAWLOWSKI, Nikolaus , GRITZAN, Uwe , BUCHMANN, Pascale , BERTLING, Christian , VON AHSEN, Oliver , NADLER, Wiebke, Maria , TSENG, Su-Yi , PAZ, Pedro , OH, Phaik, Lyn , JONES, Patrick , GORJANACZ, Matyas
IPC分类号： C07K16/24 , A61K38/00 , A61K2039/505 , A61K31/337 , A61K31/555 , A61K31/704 , A61K45/06 , A61N2005/1098 , A61P35/00 , C07K16/18 , C07K16/2866 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.

2. 发明申请

WO2021152186A2 CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS 审中-公开
公开(公告)号：WO2021152186A2
公开(公告)日：2021-08-05
申请号：PCT/EP2021/067504
申请日：2021-06-25
申请人： BAYER AKTIENGESELLSCHAFT , BAYER HEALTHCARE LLC , BAYER INTELLECTUAL PROPERTY GMBH
发明人： FILARSKY, Katharina , VON AHSEN, Oliver , BERNDT, Sandra , NADLER, Wiebke, Maria , ELLINGER, Philipp , STELTE-LUDWIG, Beatrix , HOFF, Sabine , ROIDER, Helge , WEBER, Ernst , TRAUTWEIN, Mark , VOTSMEIER, Christian , PAWLOWSKI, Nikolaus , GRITZAN, Uwe , BUCHMANN, Pascale , BERTLING, Christian , TSENG, Su-Yi , PAZ, Pedro , OH, Phaik, Lyn , JONES, Patrick , GORJANACZ, Matyas
IPC分类号： C07K16/28 , A61P35/00
摘要： The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the disclosed antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.

3. 发明申请

WO2021260208A2 SULFATED PEPTIDES FOR CHEMOKINE RECEPTOR ANTIBODY GENERATION 审中-公开
公开(公告)号：WO2021260208A2
公开(公告)日：2021-12-30
申请号：PCT/EP2021/067578
申请日：2021-06-25
申请人： BAYER AKTIENGESELLSCHAFT , BAYER HEALTHCARE LLC , BAYER INTELLECTUAL PROPERTY GMBH
发明人： BERNDT, Sandra , FILARSKY, Katharina , ELLINGER, Philipp , STELTE-LUDWIG, Beatrix , HOFF, Sabine , ROIDER, Helge , WEBER, Ernst , TRAUTWEIN, Mark , VOTSMEIER, Christian , PAWLOWSKI, Nikolaus , GRITZAN, Uwe , BUCHMANN, Pascale , BERTLING, Christian , VON AHSEN, Oliver , NADLER, Wiebke, Maria , TSENG, Su-Yi , PAZ, Pedro , OH, Phaik, Lyn , JONES, Patrick , GORJANACZ, Matyas
IPC分类号： A61K38/00 , A61K38/19 , C07K16/24 , C07K16/28 , A61P35/00 , C07K16/18 , A61K2039/505 , A61K31/337 , A61K31/555 , A61K31/704 , A61K45/06 , A61N2005/1098 , C07K16/2866 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.

4. 发明申请

WO2021260209A2 CCR8 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2021260209A2
公开(公告)日：2021-12-30
申请号：PCT/EP2021/067579
申请日：2021-06-25
申请人： BAYER AKTIENGESELLSCHAFT , BAYER HEALTHCARE LLC , BAYER INTELLECTUAL PROPERTY GMBH
发明人： BERNDT, Sandra , FILARSKY, Katharina , ELLINGER, Philipp , STELTE-LUDWIG, Beatrix , HOFF, Sabine , ROIDER, Helge , WEBER, Ernst , TRAUTWEIN, Mark , VOTSMEIER, Christian , PAWLOWSKI, Nikolaus , GRITZAN, Uwe , BUCHMANN, Pascale , BERTLING, Christian , VON AHSEN, Oliver , NADLER, Wiebke, Maria , TSENG, Su-Yi , PAZ, Pedro , OH, Phaik, Lyn , JONES, Patrick , GORJANACZ, Matyas
IPC分类号： A61K38/00 , C07K16/24 , A61K2039/505 , A61K31/337 , A61K31/555 , A61K31/704 , A61K45/06 , A61N2005/1098 , A61P35/00 , C07K16/18 , C07K16/2866 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti -human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-intemalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.

5. 发明申请

WO2021260206A2 CHEMOKINE RECEPTOR ANTIBODIES BINDING SULFATED TRD MOTIFS 审中-公开
公开(公告)号：WO2021260206A2
公开(公告)日：2021-12-30
申请号：PCT/EP2021/067574
申请日：2021-06-25
申请人： BAYER AKTIENGESELLSCHAFT , BAYER HEALTHCARE LLC , BAYER INTELLECTUAL PROPERTY GMBH
发明人： BERNDT, Sandra , FILARSKY, Katharina , ELLINGER, Philipp , STELTE-LUDWIG, Beatrix , HOFF, Sabine , ROIDER, Helge , WEBER, Ernst , TRAUTWEIN, Mark , VOTSMEIER, Christian , PAWLOWSKI, Nikolaus , GRITZAN, Uwe , BUCHMANN, Pascale , BERTLING, Christian , VON AHSEN, Oliver , NADLER, Wiebke, Maria , TSENG, Su-Yi , PAZ, Pedro , OH, Phaik, Lyn , JONES, Patrick , GORJANACZ, Matyas
IPC分类号： C07K16/24 , A61K38/00 , A61K2039/505 , A61K31/337 , A61K31/555 , A61K31/704 , A61K45/06 , A61N2005/1098 , A61P35/00 , C07K16/18 , C07K16/2866 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.

6. 发明申请

WO2011014890A1 MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF 审中-公开
标题翻译：改性因子IX多糖及其用途
公开(公告)号：WO2011014890A1
公开(公告)日：2011-02-03
申请号：PCT/US2010/044177
申请日：2010-08-02
申请人： BAYER HEALTHCARE LLC , BROOKS, Alan , PATEL, Chandra , JIANG, Xiaoqiao , GRITZAN, Uwe , APELER, Heiner , WANG, Jun
发明人： BROOKS, Alan , PATEL, Chandra , JIANG, Xiaoqiao , GRITZAN, Uwe , APELER, Heiner , WANG, Jun
IPC分类号： A61K38/36
CPC分类号： C12N9/644 , A61K38/00 , C12Y304/21022
摘要： The invention relates to modified Factor IX polypeptides such as Factor IX polypeptides with one or more amino acid substitutions. The invention also relates to methods of making modified Factor IX polypeptides, and methods of using modified Factor IX polypeptides, for example, to treat patients afflicted with hemophilia B.
摘要翻译：本发明涉及修饰的因子IX多肽，例如具有一个或多个氨基酸取代的因子IX多肽。本发明还涉及制备修饰的因子IX多肽的方法，以及使用修饰的因子IX多肽的方法，例如治疗患有血友病B的患者。

7. 发明申请

WO2009137254A2 MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF 审中-公开
标题翻译：改性因子IX多糖及其用途
公开(公告)号：WO2009137254A2
公开(公告)日：2009-11-12
申请号：PCT/US2009/040813
申请日：2009-04-16
申请人： BAYER HEALTHCARE LLC , BAYER HEALTHCARE AG , BROOKS, Alan , MURPHY, John, E. , SETO, Marian , JIANG, Xiaoqiao , PATEL, Chandra , GRITZAN, Uwe , KIRCHNER, Kornelia , HAUPTS, Ulrich
发明人： BROOKS, Alan , MURPHY, John, E. , SETO, Marian , JIANG, Xiaoqiao , PATEL, Chandra , GRITZAN, Uwe , KIRCHNER, Kornelia , HAUPTS, Ulrich
IPC分类号： A61K38/36
CPC分类号： C12N9/644 , A61K38/00 , C12Y304/21022
摘要： The invention relates to modified Factor IX polypeptides such as Factor IX polypeptides with one or more introduced glycosylation sites. The modified Factor IX polypeptides may exhibit increased in vitro or in vivo stability such as a longer plasma half-life. The invention also relates to methods of making modified Factor IX polypeptides, and methods of using modified Factor IX polypeptides, for example, to treat patients afflicted with hemophilia B.
摘要翻译：本发明涉及修饰的因子IX多肽，例如具有一个或多个引入的糖基化位点的因子IX多肽。修饰的因子IX多肽可以表现出增加的体外或体内稳定性，例如更长的血浆半衰期。本发明还涉及制备修饰的因子IX多肽的方法，以及使用修饰的因子IX多肽的方法，例如治疗患有血友病B的患者。

8. 发明申请

WO2014153195A1 MONOCLONAL ANTIBODIES AGAINST ANTITHROMBIN BETA COMPLEXED WITH HEPARIN 审中-公开
标题翻译：单克隆抗体与抗丙型肝炎复合抗体
公开(公告)号：WO2014153195A1
公开(公告)日：2014-09-25
申请号：PCT/US2014/029541
申请日：2014-03-14
申请人： BAYER HEALTHCARE LLC , JIN, Ye , MURPHY, John, E. , HERMISTON, Terry , MYLES, Timothy , DITTMER, Frank , STRERATH, Michael , GRITZAN, Uwe
发明人： JIN, Ye , MURPHY, John, E. , HERMISTON, Terry , MYLES, Timothy , DITTMER, Frank , STRERATH, Michael , GRITZAN, Uwe
IPC分类号： C07K16/38 , C12N15/13 , A61K39/395 , A61P7/04
CPC分类号： C07K16/36 , A61K38/4846 , A61K45/06 , C07K16/18 , C07K16/38 , C07K2317/21 , C07K2317/32 , C07K2317/33 , C07K2317/55 , C07K2317/565
摘要： This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin β complexed with heparin and/or heparin-like structure (ΑΤβΗ). These ΑΤβΗ binding proteins can block the anti-coagulant activity of ΑΤβ to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.
摘要翻译：该专利文献涉及针对人抗凝血酶的抗体，抗原结合抗体片段（Fabs）和其它蛋白质支架; 与肝素和/或肝素样结构复合（＆Agr;＆Tgr＆amp;＆amp; Grgr。）。这些＆Agr＆amp;＆Tgr＆结合蛋白可以阻断“抗菌素”的抗凝血活性。诱导凝血。这些抗体和结合物的治疗用途在本文中描述为淘选和筛选特异性抗体的方法。

9. 发明申请

WO2014152530A1 VARIANT FACTOR VIII POLYPEPTIDES AND METHODS OF THEIR PRODUCTION AND USE 审中-公开
标题翻译：变异因子VIII多肽及其生产和使用方法
公开(公告)号：WO2014152530A1
公开(公告)日：2014-09-25
申请号：PCT/US2014/027443
申请日：2014-03-14
申请人： BAYER HEALTHCARE LLC
发明人： GRITZAN, Uwe , KRETSCHMER, Peter , LEONG, Lilley , PATEL, Chandra
IPC分类号： A61K35/14 , C07K1/00 , C07K14/00 , A61K38/37 , C07K14/755
CPC分类号： C07K14/755 , A61K38/37
摘要： This disclosure relates to variant Factor VIII polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant Factor VIII polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop. In further embodiments, the variant factor VIII polypeptide further comprises one or more amino acid substitutions within the A1-A2 domain interface and the A2-A3 domain interface. The present disclosure further relates to methods of producing and/or using such variant Factor VIII polypeptides; nucleic acids encoding the polypeptides; vectors and/or recombinant cells, tissues, or organisms containing such nucleic acids; and kits and pharmaceutical compositions containing such polypeptides and/or nucleic acids.
摘要翻译：本公开涉及在凝血酶切割位点和激活环之一或两者内的一个或多个位置处包含氨基酸取代的变体因子VIII多肽。在某些实施方案中，变体因子VIII多肽在凝血酶切割位点和活化环两者中都包含一个或多个氨基酸取代。在另外的实施方案中，变体因子VIII多肽还包含在A1-A2结构域界面和A2-A3结构域界面内的一个或多个氨基酸取代。本公开还涉及产生和/或使用这种变体因子VIII多肽的方法; 编码多肽的核酸; 载体和/或重组细胞，组织或含有此类核酸的生物; 以及含有这种多肽和/或核酸的试剂盒和药物组合物。

10. 发明申请

WO2019105972A1 ILDR2 ANTAGONISTS AND COMBINATIONS THEREOF 审中-公开
公开(公告)号：WO2019105972A1
公开(公告)日：2019-06-06
申请号：PCT/EP2018/082779
申请日：2018-11-28
申请人： BAYER AKTIENGESELLSCHAFT , BAYER PHARMA AKTIENGESELLSCHAFT , COMPUGEN LTD.
发明人： RÖSE, Lars , GRITZAN, Uwe , HÜTTER, Julia , LIANG, Spencer , POW, Andrew , HUNTER, John , LEVY, Ofer , VAKNIN, Ilan
IPC分类号： A61K39/395 , A61K31/337 , C07K16/28 , A61P37/04 , A61P35/00
摘要： The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式